Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$9.59 - $50.88 $7.19 Million - $38.2 Million
-750,000 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$49.53 - $68.4 $4.95 Million - $6.84 Million
100,000 Added 15.38%
750,000 $38.4 Million
Q4 2020

Feb 11, 2021

BUY
$47.25 - $65.16 $30.7 Million - $42.4 Million
650,000 New
650,000 $40.2 Million
Q1 2018

May 10, 2018

SELL
$5.9 - $14.99 $2.95 Million - $7.5 Million
-500,000 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$6.5 - $10.69 $3.25 Million - $5.35 Million
500,000
500,000 $3.71 Million

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.